vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2017-2-133-138vtio-761Research ArticleОбзор литературыLiterature ReviewsИспользование амиодарона у реципиентов в листе ожидания трансплантации сердцAmiodarone in cardiac transplant waiting list patients with severe heart failureКолосковаН. Н.KoloskovaN. N.ПопцовВ. Н.PoptsovV. N.poptsov_vit@mail.ruСалиховаГ. М.SalikhovaG. M.ФГБУ «Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov Federal Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian Federation201723062017192133138Copyright © Колоскова Н.Н., Попцов В.Н., Салихова Г.М., 20172017Колоскова Н.Н., Попцов В.Н., Салихова Г.М.Koloskova N.N., Poptsov V.N., Salikhova G.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/761

Единственным радикальным методом лечения хронической сердечной недостаточности остается трансплантация сердца. В качестве профилактики внезапной сердечной смерти и лечения желудочковых нарушений ритма у пациентов с терминальной стадией сердечной недостаточности широко используется антиаритмическая терапия амиодароном. Учитывая длительный период полувыведения препарата из организма, его влияние на течение послеоперационного периода, функцию трансплантата и показатели выживаемости остается дискутабельным. Цель настоящего обзора – проанализировать данные литературы, касающиеся влияния предтрансплантационного применения амиодарона на течение послеоперационного периода, функцию трансплантата и летальность в ранние сроки после трансплантации сердца.

Heart transplantation is the «gold standard» of severe heart failure treatment. Sudden arrhythmic death is the leading cause of death among these patients. Amiodarone is the only antiarrhythmic drug with beneficial effect on survival of patients with end-stage heart failure. Given its long half-life, pre-transplant use of amiodarone has been extensively discussed focusing on divergent results regarding morbidity and mortality after heart transplantation. Its adverse clinical events after transplantation remain debatable. This review is aimed at evaluation of the impact of amiodarone pretransplant use on mortality and complications after heart transplantation.

амиодаронвыживаемость реципиентовлекарственное взаимодействиетрансплантация сердцаиммуносупрессивная терапияamiodaronecardiac recipient survivaldrug interactionheart transplantationimmunosuppressive therapyReferencesHyoung-Seob Park, Yoon-Nyun Kim. Adverse effects of long-term amiodarone therapy. Korean J. Intern. Med. 2014; 29 (5): 571–573.Hyoung-Seob Park, Yoon-Nyun Kim. Adverse effects of long-term amiodarone therapy. Korean J. Intern. Med. 2014; 29 (5): 571–573.Pedersen CT, Kay GN, Kalman J. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014; 11 (10): 166–196.Pedersen CT, Kay GN, Kalman J. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias. Heart Rhythm. 2014; 11 (10): 166–196.January CT, Wann LS, Alpert JS. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2014; 64 (21): 1–76.January CT, Wann LS, Alpert JS. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 2014; 64 (21): 1–76.Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ. Arrhythm. Electrophysiol. 2010; 3 (5): 553–559.Saravanan P, Davidson NC. Risk assessment for sudden cardiac death in dialysis patients. Circ. Arrhythm. Electrophysiol. 2010; 3 (5): 553–559.Jennings DL, Martinez B, Montalvo S, Lanfear DE. Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. Heart Fail. Rev. 2015; 20 (5): 573–578.Jennings DL, Martinez B, Montalvo S, Lanfear DE. Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. Heart Fail. Rev. 2015; 20 (5): 573–578.Chin C, Feindel C, Cheng D. Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation. J. Cardiothorac. Vasc. Anesth. 1999; 13 (5): 562–566.Chin C, Feindel C, Cheng D. Duration of preoperative amiodarone treatment may be associated with postoperative hospital mortality in patients undergoing heart transplantation. J. Cardiothorac. Vasc. Anesth. 1999; 13 (5): 562–566.Heger JJ, Prystowsky EN, Jackman WM. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia. N. Engl. J. Med. 1981; 305: 539–545.Heger JJ, Prystowsky EN, Jackman WM. Amiodarone: clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia. N. Engl. J. Med. 1981; 305: 539–545.The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am. J. Cardiol. 1993; 72: 280–287.The CASCADE Investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE study). Am. J. Cardiol. 1993; 72: 280–287.Sim I, McDonald KM, Lavori PW. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation. 1997; 96: 2823–2829.Sim I, McDonald KM, Lavori PW. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. Circulation. 1997; 96: 2823–2829.A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med. 1997; 337: 1576–1583.A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med. 1997; 337: 1576–1583.Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101: 1297–1302.Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation. 2000; 101: 1297–1302.Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102: 748–754.Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000; 102: 748–754.Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 1996; 335: 1933–1940.Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med. 1996; 335: 1933–1940.Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 1999 16; 341 (25): 1882–1890.Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med. 1999 16; 341 (25): 1882–1890.Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 2002; 346 (12): 877–883.Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP et al. Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 2002; 346 (12): 877–883.Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K et al. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. J. Am. Med. Assn. 2006; 295: 165–171.Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K et al. Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators. Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial. J. Am. Med. Assn. 2006; 295: 165–171.Boriani G,Cimaglia P, Biffi M, Martignani C, Ziacchi M, Valzania C, Diemberger I. Cost-effectiveness of implantable cardioverter-defibrillator in today’s world. Indian Heart J. 2014; 66 (Suppl 1): S101–S104.Boriani G,Cimaglia P, Biffi M, Martignani C, Ziacchi M, Valzania C, Diemberger I. Cost-effectiveness of implantable cardioverter-defibrillator in today’s world. Indian Heart J. 2014; 66 (Suppl 1): S101–S104.Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. The Lancet. 1997; 350: 1417–1424.Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. The Lancet. 1997; 350: 1417–1424.Goldschlager N, Epstein AE, Naccarelli GV. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007; 4: 1250–1259.Goldschlager N, Epstein AE, Naccarelli GV. A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm. 2007; 4: 1250–1259.Byrne JG, Leacche M, Paul S et al. Risk factors and outcomes for «vasoplegia syndrome» following cardiac transplantation. Eur. J. Cardiothorac. Surg. 2004; 25: 327–332.Byrne JG, Leacche M, Paul S et al. Risk factors and outcomes for «vasoplegia syndrome» following cardiac transplantation. Eur. J. Cardiothorac. Surg. 2004; 25: 327–332.Chemmalakuzhy J, Costanzo MR, Meyer P. Hypotension, acidosis, and vasodilatation syndrome post-heart transplant: prognostic variables and outcomes. J. Heart Lung Transplant. 2001; 20: 1075–1083.Chemmalakuzhy J, Costanzo MR, Meyer P. Hypotension, acidosis, and vasodilatation syndrome post-heart transplant: prognostic variables and outcomes. J. Heart Lung Transplant. 2001; 20: 1075–1083.Bertolet BD, Eagle DA, Conti JB. Bradycardia after heart transplantation: reversal with theophylline. J. Am. Coll. Cardiol. 1996; 28: 396–399.Bertolet BD, Eagle DA, Conti JB. Bradycardia after heart transplantation: reversal with theophylline. J. Am. Coll. Cardiol. 1996; 28: 396–399.Zimetbaum P. Amiodarone for atrial fibrillation. N. Engl. J. Med. 2007; 356: 935–941.Zimetbaum P. Amiodarone for atrial fibrillation. N. Engl. J. Med. 2007; 356: 935–941.Montero JA, Anguita M, Concha M et al. Pacing requirements after orthotopic heart transplantation: incidence and related factors. J. Heart Lung Transplant. 1992; 11 (4 Pt 1): 799–802.Montero JA, Anguita M, Concha M et al. Pacing requirements after orthotopic heart transplantation: incidence and related factors. J. Heart Lung Transplant. 1992; 11 (4 Pt 1): 799–802.Bertolet BD, Eagle DA, Conti JB, Mills RM, Belardinelli L. Bradycardia after heart transplantation: Reversal with theophylline. Journal of the American College of Cardiology. 1996; (28): 396–399.Bertolet BD, Eagle DA, Conti JB, Mills RM, Belardinelli L. Bradycardia after heart transplantation: Reversal with theophylline. Journal of the American College of Cardiology. 1996; (28): 396–399.Bacal F, Bocchi EA., Vieira ML. Permanent and temporary pacemaker implantation after orthotopic heart transplantation. Arq. Bras. Cardiol. 2000; 74: 9–12.Bacal F, Bocchi EA., Vieira ML. Permanent and temporary pacemaker implantation after orthotopic heart transplantation. Arq. Bras. Cardiol. 2000; 74: 9–12.Zieroth S, Ross H, Rao V. Permanent pacing after cardiac transplantation in the era of extended donors. J. Heart Lung Tranplant. 2006; 25 (9): 1142–1147.Zieroth S, Ross H, Rao V. Permanent pacing after cardiac transplantation in the era of extended donors. J. Heart Lung Tranplant. 2006; 25 (9): 1142–1147.Woo GW, Schofield RS, Paul DF. Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: an 11-year retrospective analysis. Transplantation. 2008; 85: 1216–1218.Woo GW, Schofield RS, Paul DF. Incidence, predictors, and outcomes of cardiac pacing after cardiac transplantation: an 11-year retrospective analysis. Transplantation. 2008; 85: 1216–1218.Готье СВ. Иммуносупрессия при трансплантации солидных органов. М., 2011: 28–33. Gautier SV. Immunosupressiya pri transplantacii solidnyh organov. M., 2011: 28–33.Готье СВ. Иммуносупрессия при трансплантации солидных органов. М., 2011: 28–33. Gautier SV. Immunosupressiya pri transplantacii solidnyh organov. M., 2011: 28–33.Preuner JG, Lehle K, Keyser A, Merk J. Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients. Transplant. Proc. 1998; 30: 3943–3944.Preuner JG, Lehle K, Keyser A, Merk J. Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients. Transplant. Proc. 1998; 30: 3943–3944.Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone–sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr. Transplant. 2006; 10: 736–739.Nalli N, Stewart-Teixeira L, Dipchand AI. Amiodarone–sirolimus/tacrolimus interaction in a pediatric heart transplant patient. Pediatr. Transplant. 2006; 10: 736–739.Kisters K, Cziborra M, Funke C. Amiodarone-tacrolimus interaction in kidney transplantation. Clin. Nephrol. 2008; 70: 563–567.Kisters K, Cziborra M, Funke C. Amiodarone-tacrolimus interaction in kidney transplantation. Clin. Nephrol. 2008; 70: 563–567.Schwarz ER, Czer LS, Simsir SA, Kass RM, Trento A. Amiodarone-induced QT prolongation in a newly transplanted heart associated with recurrent ventricular fibrillation. Cardiovasc. J. Afr. 2010; 21–2: 109–112.Schwarz ER, Czer LS, Simsir SA, Kass RM, Trento A. Amiodarone-induced QT prolongation in a newly transplanted heart associated with recurrent ventricular fibrillation. Cardiovasc. J. Afr. 2010; 21–2: 109–112.Burger CI, Clase CM, Gangji AS. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation. 2010; 15 (89): 1166–1167.Burger CI, Clase CM, Gangji AS. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation. 2010; 15 (89): 1166–1167.Macdonald P, Hackworthy R, Keogh A. The effect of chronic amiodarone therapy before transplantation on early cardiac allograft function. J. Heart Lung Transplant. 1999; 10 (5pt1): 743–749.Macdonald P, Hackworthy R, Keogh A. The effect of chronic amiodarone therapy before transplantation on early cardiac allograft function. J. Heart Lung Transplant. 1999; 10 (5pt1): 743–749.Blomberg PJ, Feingold D, Denofrio D, Rand W, Konstam MA, Estes M, Link MS. Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. Am. J. Cardiol. 2004; 93: 379–381.Blomberg PJ, Feingold D, Denofrio D, Rand W, Konstam MA, Estes M, Link MS. Comparison of survival and other complications after heart transplantation in patients taking amiodarone before surgery versus those not taking amiodarone. Am. J. Cardiol. 2004; 93: 379–381.Yerebakan H, Naka Y, Sorabella R. Amiodarone treatment prior to heart transplantation is associated with acute graft dysfunction and early mortality: a propensitymatched comparison. J. Heart Lung Transplant. 2014; 33: S105.Yerebakan H, Naka Y, Sorabella R. Amiodarone treatment prior to heart transplantation is associated with acute graft dysfunction and early mortality: a propensitymatched comparison. J. Heart Lung Transplant. 2014; 33: S105.Cooper LB, Mentz RJ, Edwards LB, Wilk AR, Rogers JG, Patel CB et al. Amiodarone use in patients listed for heart transplant is associated with increased 1-year posttransplant mortality. J. Heart Lung Transplant. 2017; 36: 202–210.Cooper LB, Mentz RJ, Edwards LB, Wilk AR, Rogers JG, Patel CB et al. Amiodarone use in patients listed for heart transplant is associated with increased 1-year posttransplant mortality. J. Heart Lung Transplant. 2017; 36: 202–210.Chelimsky-Fallick C, Middlekauff HR, Stevenson WG. Amiodarone therapy does not compromise subsequent heart transplantation. J. Am. Coll. Cardiol. 1992; 20 (7): 1556–1561.Chelimsky-Fallick C, Middlekauff HR, Stevenson WG. Amiodarone therapy does not compromise subsequent heart transplantation. J. Am. Coll. Cardiol. 1992; 20 (7): 1556–1561.

The authors declare that there are no conflicts of interest present.